



ANNUAL REPORT

2024

**CANCER DRUG DEVELOPMENT FORUM
(CDDF)**

www.cddf.org
info@cddf.org

Table of Contents

1. The Year in Review	02
2. About the CDDF	04
3. Organisational Structure	05
4. Leadership	06
5. CDDF Office	09
6. Financial Statement	10
7. Achievements	12
8. Sustainability	28
9. Acknowledgement of Supporters	29
10 CDDF in 2025: A Look Ahead	31
11. Appendix	34

The Year in Review



2024, Year of Fruitful Collaboration

Dear CDDF community,

2024 has been a year of remarkable progress for the CDDF, a year marked by fruitful collaborations that have solidified our position as the truly neutral and collaborative multi-stakeholder platform within the oncology community. I am incredibly proud of the strides we have made, and it is a privilege to share with you the highlights of our achievements.

Our diverse collaborations, spanning across Europe and the globe, have been the cornerstone of our success. They have enabled the CDDF to effectively drive forward our mission to improve outcomes for cancer patients in the rapidly evolving landscape of cancer care. These partnerships, built on a shared commitment to progress, have fostered meaningful dialogue and generated impactful results. They have not only validated our collaborative approach but have also amplified our collective impact on the entire cancer community. It is through these shared efforts that we can make a difference in the lives of those affected by cancer.



In 2024, the CDDF has been involved in a range of activities and initiatives, all designed to advance cancer care. Our collaboration with ESMO at their 2024 Congress, through the [ESMO-CDDF Educational Session on Regulatory Challenges in Clinical Cancer Drug Development](#), allowed us to connect with a wider range of stakeholders across Europe. Another fruitful collaboration, the [CDDF-EORTC joint workshop: Innovation and Access in Rare Cancers](#), represented a step forward in enhancing care for patients with rare cancers, an underserved group whose specific needs often require tailored approaches.

The CDDF has continued fostering open discussion on innovation in cancer research, recognizing its crucial role in improving patient outcomes. Our programs addressed a variety of crucial topics, reflecting the fast-evolving field of oncology. These topics included real-world evidence, decentralized care and trials, drug and biomarker combinations, AI and big data, Bayesian approaches in drug development and many more.

Highlighting the importance of equitable access to clinical trials, we also dedicated a program to looking into access to [clinical trials in Central and Eastern Europe](#) and exploring next levels of development. This meeting gathered key stakeholders to improve patient access to innovative therapies in these regions, helping to ensure that all patients, regardless of their location, have the opportunity to benefit from the latest advances in cancer treatment.



The Year in Review



In addition, the CDDF undertook new efforts in engagement last year. Firstly, we launched an initiative on [Diversity in oncology clinical trials](#), forming a multi-stakeholder working group to support the planning and evaluation of clinical research. Secondly, we were selected as an ad-hoc representative of the [Multi-Stakeholder Platform Advisory Group \(MSP AG\)](#) under the Accelerating Clinical Trials in the EU (ACT EU), giving us a platform to further contribute to improving the clinical trials environment for European patients and citizens. Lastly, we broadened our network with new industry members, ranging from SMEs to a large company, and a non-commercial organization, the Friends of Cancer Research, enriching our collaborative ecosystem and bringing diverse perspectives to our work.

Last but not least, the CDDF translated its work into tangible outputs that have a real impact on the oncology community. In 2024, we published white papers and a journal chapter, which served as valuable resources for stakeholders and contributed to shaping best practices in cancer care. They include:

- **Empowering Effective Biomarker-Driven Precision Oncology: A Call to Action**
- **Histology Independent Drug Development – Is This the Future for Cancer Drugs?**
- **Pragmatic Solutions for Optimizing Oncology Drug Development Trials**

Looking ahead to 2025, the CDDF remains committed to its mission of fostering collaboration and driving progress in cancer care. We plan to continue our discussions on topical issues and advancements in cancer drug development, including endpoints, precision oncology development, radiopharmaceuticals, personalized vaccines in oncology, cellular therapies, AI and big data, the Bayesian framework, and new regulations. Maintaining close collaboration with a diverse range of stakeholders, the CDDF will continue its participation in/organization of EU-level initiatives, and sustained engagement at the global level.

The CDDF's accomplishments in 2024 are a testament to the dedication and hard work of our staff, board, members, and collaborators for those affected by cancers. I am confident that in 2025, we will continue to build on this momentum, making even greater strides towards improving the lives of cancer patients. Thank you for your support and engagement with the CDDF. Together, we can make a real difference.

Yours sincerely,

Prof. Ruth Plummer

Chairperson of the CDDF Board of Director

ABOUT THE CDDF



WHAT IS THE CDDF?

The Cancer Drug Development Forum (CDDF) is a **non-profit organisation** registered in Belgium that provides a **neutral platform** to stimulate **interaction between stakeholders** involved in cancer drug development.

CDDF'S MISSION

The CDDF's mission is to facilitate collaboration between stakeholders, to **increase efficiency** in cancer drug development and **accelerate the delivery of effective oncology treatment to patients**.


HOW DOES THE CDDF ADVANCE ITS MISSION?

To accomplish its mission, the CDDF offers workshops, conferences and webinars that bring together leading voices from academia, the pharmaceutical industry, regulatory authorities, health technology assessors, policymakers, and patient groups. By providing a non-competitive, non-commercial platform for multi-stakeholder discussions and collaboration, the CDDF stimulates advancement and innovation in the field through scientific debate and open discussion.

Since August 2024, the CDDF Diversity Initiative has started to support the planning and evaluation of clinical research for European populations. The CDDF also serves as an ad hoc representative of the Multi-Stakeholder Platform Advisory Group (MSP AG) under the Accelerating Clinical Trials in the EU (ACT EU).



ORGANISATIONAL STRUCTURE



Ruth Plummer
Chairperson

Stefan Symeonides
Vice-Chairperson

Axel Glasmacher
Treasurer

Jaap Verweij
Managing Director

Catarina Edfjäll
Board member

Rosa Giuliani
Board member

Mark Lawler
Board member

Christian Schneider
Board member

Fergus Sweeney
Board member

Eva Skovlund
Board member



Jaap Verweij
Managing Director

Marjorie Recorbet
Director of Operations

Giorgia Campagnano
Event Manager

Caroline Marissal
Event Coordinator

Hyunmin Park
Communication/Community Coordinator

LEADERSHIP



GOVERNANCE

CDDF Board of Directors

The CDDF is governed by a rotating board of directors dedicated to the development of cancer drugs. These distinguished academics are experienced pre-clinical and clinical investigators, medical oncologists, regulatory scientists and a statistician representing a range of perspectives within the drug development process. The directors are elected for a period of three years.

Full and Honorary Members of Association

Full and honorary Members of the CDDF are committed to accelerating oncology drug development and delivering optimal treatment to cancer patients. Members have the right to attend General Assembly meetings, which take place once a year and are the association's sovereign authority. At these meetings, Members monitor, assess and guide CDDF's work programme, organisational directions and best practices.



18

Full/honorary
Members of
the association



10

CDDF Board
of Directors



4


CDDF office
staff members



LEADERSHIP



CDDF BOARD OF DIRECTORS



TOGETHER, WE IDENTIFY AND OVERCOME
CHALLENGES IN THE DEVELOPMENT AND
DELIVERY OF CANCER DRUGS

CHANGES IN BOARD COMPOSITION

In accordance with the CDDF Articles of Association, a Member of the CDDF Board of Directors is appointed for a period of three years. The mandate of the member is renewable. This rotation policy serves to develop robust governance practices within the CDDF and encourages a dynamic and diverse composition of the Board of Directors.

At the CDDF's General Assembly in May 2024, **Professor Stefan Symeonides** was nominated as new Deputy Chairperson for a three-year term, succeeding Professor Eva Skovlund. This nomination took effect on 23 May 2024 following the meeting.

CONFLICTS OF INTEREST


In accordance with the Articles of Association, Board members have declared any potential conflicts of interest. The disclosure forms are provided in the appendix (page 34).



CDDF OFFICE



OFFICE STAFF MEMBERS



EMPLOYMENT DETAILS

- » **Jaap Verweij, Managing Director**
Consultancy contract renewed until 30 September 2025
- » **Marjorie Recorbet, Director of Operations**
2.5 days/week contract
- » **Giorgia Campagnano**
4 days/week contract
- » **Caroline Marissal**
4 days/week contract
- » **Hyunmin Park**
3 day/week contract

FINANCIAL STATEMENT



REVENUE AND EXPENSES IN THE 2024 FISCAL YEAR



Total Revenue
€ 684,617.96




Total Expenses
€ 695,597.12



Balance
€ -10,979.16

TOTAL REVENUE 2024



■ Membership Fees ■ Income from events ■ Other Income




Total Revenue
€ 684,617.96




FINANCIAL STATEMENT

TOTAL EXPENSES 2024



Total Expenses

€ 695,597.12



■ Human Resources

■ Office & IT Costs

■ Legal Costs

■ Miscellaneous Expenses & Depreciation

■ Accounting Tax Management

■ Board of Directors

■ Event Organisation

ACHIEVEMENTS



OVERVIEW OF ACTIVITIES

In 2024, the CDDF broadened its stakeholder engagement to foster a more inclusive and balanced dialogue, actively involving representatives from regulatory bodies, academia, and patient advocacy groups. CDDF multi-stakeholder meetings and webinars effectively addressed emerging key topics, current challenges, and opportunities in oncology.

CDDF MEETINGS IN 2024



ANNUAL CONFERENCE

Changing Paradigms to Accelerate Oncology Drug Development

5 – 7 February 2024
Hybrid, NL



MULTI- STAKEHOLDER WORKSHOP

Clinical Research in Central and Eastern Europe: New Approaches for the Next Level of Development

15-16 April 2024
Hybrid, NL



MULTI- STAKEHOLDER WORKSHOP

Innovation and Access in Rare Cancers

23 – 24 September 2024
Hybrid, NL



ACHIEVEMENTS



OVERVIEW OF ACTIVITIES

ESMO-CDDF EDUCATIONAL SESSION



Regulatory Challenges in Clinical Cancer Drug Development

16 September 2024
In-person session

CDDF LIVE WEBINAR SERIES



COVID-19 and Cancer – Time for a Reset to Repair the Damage Done

15 January 2024



Clinical Research in Central and Eastern Europe: Realising the Opportunities

12 February 2024



Cancer Medicines Forum: Advancing Cancer Treatment Optimization Across Europe

25 June 2024



Bayesian Approaches in Drug Development

11 July 2024



AI and Big Data in Cancer Drug Development – Webinar 1: An Introduction to the Use of AI in Cancer Drug Development and Regulatory Considerations

29 October 2024



EU Clinical Trial Regulations

12 November 2024

ACHIEVEMENTS



OVERVIEW OF ACTIVITIES



Total number of CDDF meetings in 2024

3



Total number of CDDF webinars in 2024

6



Total number of participants


971



Participant overall satisfaction rate

4.7/5

Number of Participants per Meeting/Webinar




CDDF Meetings

CDDF Webinars




ACHIEVEMENTS

Categories of Onsite Meeting Participants



This graph reflects categories of onsite meeting participants in 2024 excluding CDDF staff members and N/A

Countries of Meeting Participants (onsite & online)





ACHIEVEMENTS



CDDF MEETINGS IN 2024

Annual Conference: Changing Paradigms to Accelerate Oncology Drug Development

5-7 February 2024, hybrid, Noordwijk (NL)

The annual conference 2024 explored and analyzed innovative approaches to accelerate oncology drug development, considering the changing paradigms and regulatory environment in the field. The program focused on real world evidence, decentralized care and trials, impact of recent regulatory changes, diversity in clinical trials, and drug and biomarker combinations in oncology. It also provided reflections on the CDDF workshops held in 2023 and its joint activity with AAADV and ASCO to explore global collaboration in cancer drug development.



Multi-Stakeholder Workshop: Clinical Research in Central and Eastern Europe - New Approaches for the Next Level of Development

15 - 16 April 2024, hybrid, Krakow (PL)



The workshop focused on the rapidly evolving clinical trial landscape in Central Eastern Europe (CEE) and discussed the current state of play, challenges and collaborative next steps to enhance innovation in the region. A multi-stakeholder group of experts provided insights on important topics such as patient access to innovative oncology drugs and cross-border access to clinical trials. Through in-depth discussions, attendees explored the future direction of clinical research in CEE and discussed how best to enhance patient care in the area.



ACHIEVEMENTS



CDDF MEETINGS IN 2024

Multi-Stakeholder Workshop: Innovation and Access in Rare Cancers

23 – 24 September 2024, hybrid, Amsterdam (NL)

This collaborative effort between CDDF and EORTC focused on the current state of play in clinical trials and exchanged multi-stakeholder perspectives in order to improve access to innovative therapies for patients with rare cancers. A multi-stakeholder group of experts provided insights on important topics in rare cancers such as the existing challenges, ongoing collaborations, unmet needs, innovative clinical trial designs and potential solutions to improve patient access.



ESMO 2024: ESMO-CDDF EDUCATIONAL SESSION

Regulatory Challenges in Clinical Cancer Drug Development

16 September 2024, in-person, Barcelona (ES)



The educational session on “Regulatory Challenges in Clinical Cancer Drug Development” outlined the process and timelines for CHMP approvals and illustrated to the audience how to navigate the EMA website to find current SmPCs and assessment documents.

ACHIEVEMENTS



CDDF WEBINARS IN 2024

Live Webinar: COVID-19 and Cancer – Time for a Reset to Repair the Damage Done

15 January 2024, online

The COVID-19 Pandemic and national lockdowns have had a significant impact on cancer services and cancer patients. In this webinar, we explored in detail the different impacts on cancer research and cancer care across Europe, from both a health professional and a patient perspective. We also highlighted the absolute primacy of data, both in capturing in detail the extent of the disruption, but also in providing the intelligence to help address and mitigate the challenges going forward.



Live Webinar: Clinical Research in Central and Eastern Europe: Realising the Opportunities

12 February 2024, online



This webinar gave a pre-view of the discussions that are going to take place during the hybrid CDDF “Multi-stakeholder workshop on Clinical Research in Central and Eastern Europe “New Approaches for the Next Level of Development”, taking place on 15-16 April 2024 in Krakow, Poland.



ACHIEVEMENTS



CDDF WEBINARS IN 2024

Live Webinar: Cancer Medicines Forum: Advancing Cancer Treatment Optimization Across Europe

25 June 2024, online

Under the joint leadership of the European Medicines Agency (EMA) and the European Organisation for Research and Treatment of Cancer (EORTC), the Cancer Medicines Forum (CMF) serves as a pioneering initiative. Its primary goal is to seamlessly integrate the academic sector's contributions into the regulatory decision-making process. During the hybrid workshop held on April 5 2024, the Cancer Medicines Forum presented its astute observations and preliminary solutions to address treatment optimization.

The poster for the 'Cancer Medicines Forum: Advancing Cancer Treatment Optimization Across Europe' webinar. It features the CDDF logo at the top left, a circular portrait of Denis Lacombe on the right, and the following text: 'LIVE WEBINAR', 'Cancer Medicines Forum: Advancing Cancer Treatment Optimization Across Europe', 'Denis Lacombe (EORTC, BE)', and '25 June 2024 16:00-17:00 CEST, Online'.

Live Webinar: Bayesian Approaches in Drug Development

11 July 2024, online

The poster for the 'Bayesian Approaches in Drug Development' webinar. It features the CDDF logo at the top left, a circular portrait of Robert Hemmings on the right, and the following text: 'LIVE WEBINAR', 'Bayesian Approaches in Drug Development', 'Robert Hemmings (CONSILIUM Salmonson & Hemmings)', and '11 July 2024 17:00-18:00 CEST, Online'.

The Bayesian approach is a way to formally combine knowledge from previous data or 'beliefs' with data from a study, thus formally integrating all available knowledge to make statements about the probability that certain treatment effects exist and in the estimation of their magnitude. In this CDDF webinar we discussed opportunities and challenges of expanding the use of Bayesian approaches in drug development.

ACHIEVEMENTS



CDDF WEBINARS IN 2024

AI and Big Data in Cancer Drug Development Series – 1: An introduction to the use of AI in cancer drug development and regulatory considerations

29 October 2024, Online

AI is transforming drug development by enhancing clinical operations, regulatory processes, and study design. Its specific applications in cancer research are particularly impactful. In this session, we explored the potential applications of AI in cancer drug development, highlighted specific use cases, and discussed regulatory requirements for its implementation.

The poster for the webinar features the CDDF logo at the top left. Below it, the text reads 'LIVE WEBINAR SERIES' followed by 'AI and Big Data AI in cancer drug development'. The main title is 'An introduction to the use of AI in cancer drug development and regulatory considerations'. The speaker is 'Dr Katrin Rupalla (Johnson & Johnson)'. The date and time are '29 October 2024' and '17:00-18:00 CET, Online'. On the right side, there is a circular portrait of Dr. Katrin Rupalla, a woman with short brown hair wearing a pink blazer.

Live Webinar: EU Clinical Trial Regulations

12 November 2024, online

The poster for the webinar features the CDDF logo at the top left. Below it, the text reads 'LIVE WEBINAR' followed by 'EU Clinical Trial Regulations'. The speakers are 'Stephanie Kromar (EORTC)' and 'Dr Tarec Christoffer El-Galaly (Aarhus University)'. The date and time are '12 November 2024' and '17:00-18:00 CET, Online'. On the right side, there are two circular portraits: the top one is of Stephanie Kromar, a woman with brown hair, and the bottom one is of Dr. Tarec Christoffer El-Galaly, a man with a shaved head.

The EU CTR was introduced in January 2022 and aims to harmonise the procedures for assessment, approval and supervision of clinical trials throughout the EU. Following a one year transition period all studies are submitted under this new regulation. In this webinar two experts who have been closely involved during its implementation discussed some of the challenges and benefits of the new procedure.



ACHIEVEMENTS



CDDF DIVERSITY INITIATIVE

Launched in August 2024, the CDDF Diversity Initiative is a project directed by the CDDF and guided by a multi-stakeholder working group of regulators, patients, academic researchers, and pharmaceutical companies. This initiative aims to examine parameters of inclusion/diversity in clinical research, to support the planning and evaluation of clinical research, and the applicability of clinical trial outcomes to Europe's diverse population.

KEY DELIVERABLES

- To publish a **white paper** describing the selected variables, rationale for their selection, methodological approaches, and respective best practices for clinical trials and studies from multi-stakeholder perspectives.
- To outline **open questions** for further research.

PROJECT TIMELINES

- Preparation: Aug - Sep 2024
- Phase 1: Oct 2024 - Jan 2025
- Phase 2: Feb 2025 - Feb 2027

For more on project details,
visit the CDDF website



Diversity in Oncology Clinical Trials in Europe

The CDDF Diversity Initiative: To support planning and evaluation of clinical research for European populations



ACCELERATING CLINICAL TRIALS IN THE EU (ACT EU)



CDDF as Ad-Hoc Representative of the Multi-Stakeholder Platform Advisory Group (MSP AG)

Starting in January 2024, the Cancer Drug Development Forum has been serving as an **ad-hoc representative of the Multi-Stakeholder Platform Advisory Group (MSP AG)** within the Accelerating Clinical Trials in the EU (ACT EU) initiative. This effort, led by the European Commission, the European Medicines Agency (EMA), and the Heads of Medicines Agencies (HMA), aims to transform the EU into a region that fosters clinical trial development, collaboration, and innovation throughout the clinical research lifecycle.

To achieve this, the ACT EU's Multi-stakeholder Platform (MSP) provides a space for clinical trial stakeholders and regulators to collaborate, share perspectives, and improve the clinical trials environment for European patients. It facilitates dialogue through the MSP Advisory Group, where the CDDF participates and engages. Within this channel, the CDDF contributes to enhancing the clinical trials environment for European patients by effectively amplifying the voices of key stakeholders in oncology.

MSP ADVISORY GROUP

The MSP Advisory Group (MSP AG) is composed of representatives from key stakeholders who provide:

- strategic advice regarding the ACT EU workplan, identifying stakeholder priorities.
- operational advice for ACT EU initiatives, identifying experts and engagement methodology.
- Full member list available [here](#)

CDDF'S ENGAGEMENT

Throughout 2024, CDDF participated in ACT EU's various meetings and initiatives, bringing forward multi-stakeholder perspectives gathered from CDDF discussions. Here are some of the items of interest:

- [CDDF's proposal: Enabling CTIS Public Data Use](#) (July 2024)
- [ACT EU meeting details and materials](#)

“

**CDDF MEETINGS BRING
TOGETHER REGULATORS,
HTAs, THE INDUSTRY,
ACADEMICS AND PATIENT
ADVOCATES TO
COLLABORATE**

”

**INCLUSIVE &
COLLABORATIVE NETWORK
OF MULTI-STAKEHOLDERS
INVOLVED IN ONCOLOGY
DRUG DEVELOPMENT**

ACHIEVEMENTS



COLLABORATION

Recognizing collaboration as fundamental to CDDF's mission, the association fostered and maintained cooperative relationships with diverse organizations representing key stakeholder perspectives in cancer drug development.



Accelerating Anticancer Agent Development and Validation (AAADV)

The CDDF continued its active collaboration with the AAADV, exchanging best practices and information on cancer drug development.

To prepare for the 2025 AAADV, ASCO and CDDF workshop, a think-tank meeting took place on 18 Dec 2024 to discuss priorities and needs in cancer drug development, and how the AAADV workshop could meet those needs. Jaap Verweij (CDDF Managing Director) and Ruth Plummer (CDDF Chairperson) attended the gathering and shared their insights with AAADV leadership in order to help maximize the workshop's impact on advancing cancer drug development globally.



European Federation of Pharmaceutical Industries and Associations (EFPIA)

The CDDF engaged in ongoing dialogue with the EFPIA to explore key topics, current challenges, and opportunities within oncology drug development, and to identify potential speakers for CDDF discussions.



ACHIEVEMENTS



COLLABORATION



The future of cancer therapy

European Organisation for Research and Treatment of Cancer (EORTC)

The EORTC and the CDDF reinforced their collaborative relationship by convening a multi-stakeholder workshop on rare cancers in September 2024. This joint undertaking demonstrates their mutual dedication to enhancing care for patients with rare cancers, an underserved population whose specific needs often require tailored approaches.

As part of their collaborative endeavors, the CDDF hosted live webinars with EORTC speakers, Stéphanie Kromar and Denis Lacombe, who presented on EU Clinical Trial regulations and the Cancer Medicines Forum, respectively.



European Society for Medical Oncology (ESMO)

In September 2024, the CDDF revitalized its collaboration with ESMO by organizing an Educational Session on Regulatory Challenges in Clinical Cancer Drug Development. This initiative provided stakeholders with crucial insights into EU regulatory frameworks and expanded the CDDF's engagement with a broader audience.



Friends of Cancer Research

In November 2024, the CDDF and the Friends of Cancer Research strengthened their collaboration by signing a Memorandum of Understanding (MoU) to accelerate innovative, effective cancer care. This alliance, fostering multi-stakeholder collaboration across Europe and globally, reflects their shared commitment to making a meaningful impact in the fight against cancer.



ACHIEVEMENTS



COLLABORATION




EMA & FDA

The European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA) continued their support for CDDF multi-stakeholder discussions in 2024. Both agencies provided valuable regulatory perspective on diverse topics in cancer drug development and took part in constructive discussions with the CDDF multi-stakeholder community.



The Workgroup of European Cancer Patient Advocacy Networks (WECAN)

The WECAN and the CDDF made continued efforts to advance their shared mission of improving cancer treatment for patients. WECAN representatives contributed to CDDF meetings in various capacities, facilitating the integration of the patient perspective into multi-stakeholder dialogues.



ENVIRONMENTAL RESPONSIBILITY: CDDF's Green Journey to Advancing Cancer Care



The CDDF recognizes the importance of integrating environmental sustainability into every aspect of its organizational operations as it accomplishes its mission. Long before it became common practice, CDDF proactively implemented measures to minimize its ecological footprint. From reducing paper printing, reusing event materials, and digitalizing events, to selecting green venues and encouraging eco-conscious travel, CDDF has consistently strived to lead by example. This enduring commitment reflects our belief that advancing cancer care must go hand-in-hand with responsible stewardship of our planet.



CDDF'S SUSTAINABLE EFFORTS



Selecting green key venue*



Shared Transportation to Venue



Reusing event materials (badgets, banners, and lanyards)



Sustainable travel poilcy (reimbursement for CO2 offset & eco-travel)



Reducing paper printing



Reducing food waste



Digitalizing (hybrid events and digital materials)



Consistent monitoring and assessment of environmental footprint

ACKNOWLEDGEMENT OF SUPPORTERS

The CDDF thanks its members and collaborators for their engagement and invaluable contribution to support the CDDF's mission in 2024.

CDDF INDUSTRY MEMBERS IN 2024



ACKNOWLEDGEMENT OF SUPPORTERS


COLLABORATORS IN 2024



COLLABORATION AND OPEN DIALOGUE
AMONG ALL STAKEHOLDERS ARE
KEY TO IMPROVING OUTCOMES
FOR CANCER PATIENTS



CDDF IN 2025: A LOOK AHEAD



Key Discussion Topics in Cancer Drug Development

Driven by our mission to accelerate cancer care, the CDDF will continue to foster collaboration and open dialogue. Our multi-stakeholder discussions will focus on cutting-edge advancements in cancer drug development, including areas like endpoints, precision oncology development, radiopharmaceuticals, personalized vaccines in oncology, cellular therapies, AI and big data, the Bayesian framework, and new regulations.

By strengthening our collaborative relationships with diverse stakeholders and actively engaging in EU and global initiatives, CDDF will strive to amplify its impact on the future of cancer treatment.

LIVE WEBINARS

A promotional poster for a live webinar. On the left, the CDDF logo is at the top, followed by the text 'LIVE WEBINAR' and 'EU HTA Regulation'. Below this, the names of the speakers are listed: Michael Berntgen (EMA), Niklas Hedberg (TLV), and Vanessa Schaub (Roche). At the bottom, the date and time are given: '12 March 2025' and '17:00-18:00 CET, Online'. On the right side of the poster, there are three circular headshots of the speakers: Michael Berntgen at the top, Niklas Hedberg in the middle, and Vanessa Schaub at the bottom.

- AI Webinar series 2: Transparency and risk assessment
- AI Webinar series 2: Modern imaging tools for response assessment
- AI Webinar Series 3: AI-driven patient profiling for personalized treatment recommendations
- AI Webinar Series 4: Use of AI in clinical trials
- ACT EU Series: Overview of ACT EU
- ACT EU Series: Patients - CTIS

CDDF IN 2025: A LOOK AHEAD



MULTI-STAKEHOLDER MEETINGS

Cancer Drug Development Forum (CDDF)

ANNUAL CONFERENCE 2025

**Challenges, Advances,
and Open Questions in
Global Cancer Drug
Development and
Clinical Trials**

3-5 February 2025
Noordwijk aan Zee, NL

A circular graphic with a green border. Inside, there's a smaller circle with the CDDF logo and the text 'Annual Conference 2025'. To the right of the logo, there are four overlapping circles labeled 'FACILITATE', 'DEBATE', 'ACTIVATE', and 'INNOVATE'.

Focus of Discussion

- 1 Diversity in Global Drug Development
- 2 Endpoints in Drug Development
- 3 Optimize Evidence Generation And Patient Access with Innovative Cancer Trials
- 4 Navigating Precision Oncology Development in View of New Regulations
- 5 EU HTA Regulations - Stakeholder Collaboration to Improve Patient Access

The logo for the Cancer Drug Development Forum (CDDF) features a cluster of blue dots of varying sizes on the left, followed by the text 'CDDF' in a bold, blue, sans-serif font, and 'Cancer Drug Development Forum' in a smaller, lighter blue font below it.

MULTI-STAKEHOLDER WORKSHOP

New Modalities in Cancer Drug Development

31 March - 1 April 2025
Brussels, BE (hybrid)



Focus of Discussion

- 1 What Is New in Oncology
- 2 Radiopharmaceuticals
- 3 Personalized Vaccines in Oncology
- 4 Cellular Therapies
- 5 Discussion on Common Challenges



CDDF IN 2025: A LOOK AHEAD




MULTI-STAKEHOLDER MEETINGS



Focus of Discussion

- 1 Keynote Lectures & Fireside Chat
- 2 Endpoints/Post-Authorisation
- 3 Use of Pragmatic Elements During the Drug Development Lifecycle
- 4 Real World Data and Safety
- 5 Wrap-up and Next Steps

AAADV-ASCO-CDDF WORKSHOP



DISCLOSURE OF CONFLICTS OF INTEREST FOR CDDF LEADERSHIP

Prof. Ruth Plummer

Commercial organizations with actual/potential/perceived conflicts of interest of a financial/functional/any other nature

- Honoria for attending advisory boards from Pierre Faber, Bayer, Novartis, BMS, Ellipses, Immunocore, Genmab, Astex Therapeutics, MSD, Nerviano, AmLo, Incyte, Cybrexa
- Benevolent AI and Sanofi Aventis.
- Honoraria for working as an IDMC member for Alligator Biosciences, GSK, Onxeo, SOTIO, Biotech AG, and AstraZeneca
- Payment for the delivery of educational talks or chairing educational meetings from AstraZeneca, Novartis, Bayer, MSD and BMS.

Non-commercial organizations with actual/potential/perceived conflict of interest of a financial/functional/any other nature

- No partnerships to disclose.

22 January 2024

Prof. Eva Skovlund

Commercial organizations with actual/potential/perceived conflict of interest of a financial/functional/any other nature

- None

Non-commercial organizations with actual/potential/perceived conflict of interest of a financial/functional/any other nature

- None

22 January 2024

DISCLOSURE OF CONFLICTS OF INTEREST FOR CDDF LEADERSHIP

Prof. Jaap Verweij

Commercial organizations with actual/potential/perceived conflict of interest of a financial/functional/any other nature

- IDRX (serving as consulting Medical Monitor)
- Deuter Oncology (serving as consulting CMO)

Non-commercial organizations with actual/potential/perceived conflict of interest of a financial/functional/any other nature

- None

13 January 2025

Prof. Axel Glasmacher

Commercial organizations with actual/potential/perceived conflict of interest of a financial/functional/any other nature

- Member of Board of Directors (Current)
 - Active Biotech AB
 - Ryvu Pharmaceuticals
- Consultancy (2023-2024)
 - Active Biotech AB
 - Nanexa AB
 - Cellex GmbH
 - Ryvu Therapeutics S.A.
 - Oncopeptides AB
 - Excerpta Medica BV
 - Healthcare Royalty Management

Non-commercial organizations with actual/potential/perceived conflict of interest of a financial/functional/any other nature

- None

22 November 2024

DISCLOSURE OF CONFLICTS OF INTEREST FOR CDDF LEADERSHIP

Dr. Catarina Edfjäll

Commercial organizations with actual/potential/perceived conflict of interest of a financial/functional/any other nature

- None

Non-commercial organizations with actual/potential/perceived conflict of interest of a financial/functional/any other nature

- None

5 February 2024

Prof. Mark Lawler

Commercial organizations with actual/potential/perceived conflict of interest of a financial/functional/any other nature

- Honoraria from Bayer, Carnall Farrar, EMD Serono, Novartis, Pfizer and Roche

Non-commercial organizations with actual/potential/perceived conflict of interest of a financial/functional/any other nature

- None

28 March 2023

Dr. Rosa Giuliani

Commercial organizations with actual/potential/perceived conflict of interest of a financial/functional/any other nature

- None

Non-commercial organizations with actual/potential/perceived conflict of interest of a financial/functional/any other nature

- None

3 February 2024

DISCLOSURE OF CONFLICTS OF INTEREST FOR CDDF LEADERSHIP

Dr. Christian Schneider

Commercial organizations with actual/potential/perceived conflict of interest of a financial/functional/any other nature

- Working as a consultant with multiple pharmaceutical companies across all products and indications in the biopharmaceutical space.
- Salary from Cencora without any direct interest in any company

Non-commercial organizations with actual/potential/perceived conflict of interest of a financial/functional/any other nature

- None

4 February 2024

Dr. Fergus Sweeney

Commercial organizations with actual/potential/perceived conflict of interest of a financial/functional/any other nature

- None

Non-commercial organizations with actual/potential/perceived conflict of interest of a financial/functional/any other nature

- Member of WHO Technical Advisory Group on Development of Guidance on Best Practices for Clinical Trials

22 January 2024

DISCLOSURE OF CONFLICTS OF INTEREST FOR CDDF LEADERSHIP

Prof. Stefan Symeonides

Commercial organizations with actual/potential/perceived conflict of interest of a financial/functional/any other nature

- No financial interests in any commercial pharmaceutical entity
- No personal gain from any of the below unless highlighted in **bold**
 - Educational & travel:
 - Ipsen (6/17, 6/18, 9/19, 9/21, 9/22), EUSA (6/21, 6/22), BioNTech (11/21), MSD (2/22)
 - Consultancy (my institution):
 - Nil current
 - Scientific advisory role (my institution, unless highlighted in **bold**):
 - Duke Street Bio (22/3/22 –)
 - Eisai (18/3/19, 20/12/22)
 - **Ellipses** (11/4/18 –)
 - Eugit Therapeutics (10/22 –)
 - **Exscientia** (13/8/23 –)
 - Grey Wolf Therapeutics (25/5/23 –)
 - MSD (10/5/19, 3/7/20, 4/3/21, 6/7/21, 7/7/21, 15/10/21, 17/3/22, 15/12/22)
 - Speaker (my institution, unless highlighted in **bold**):
 - Eisai (31/10/22)
 - **Ipsen** (26/10/21 clinicians; 6/11/21, 18/3/22, 30/3/23 & 21/9/23 non-promotional educational, unrelated to company's products)
 - MSD (31/3/22 internal MSD, 23/5/22 internal MSD)
 - Research funding (my institution):
 - MSD (trial funding and drug supply, trials staff) (6/15-)
 - Verastem (trial funding and drug supply) (6/15-)
 - Independent Data / Safety Monitoring (my institution, unless highlighted in **bold**):
 - **Exscientia** (13/8/23 –)
 - **WCG** (16/2/23 –)
 - Grey Wolf Therapeutics (25/5/23 –)

Continues on the next page

DISCLOSURE OF CONFLICTS OF INTEREST FOR CDDF LEADERSHIP

Prof. Stefan Symeonides

Commercial organizations with actual/potential/perceived conflict of interest of a financial/functional/any other nature

- Research collaboration (as PI/CI):
- Pharmaceutical companies
- MSD (MK3475-564 13/2/17, MK3475-U03a/b), BioNTech (5/11/19), Boston Pharmaceuticals (2/11/17 – 12/4/21), Sierra Oncology (SRA737-01, 12/4/17-12/19), Agalimmune/BioLineRx (1/5/19), Nucana (13/3/19), Nouscom (26/4/21), Sapience (18/3/20), Roche (14/6/21), Incyte (26/10/21), Scancell (ModiFY 22/4/22), Medannex (4/8/23). In set-up: AZ, Grey Wolf Therapeutics, Nuvectis, Salubris Bio, Seagen, TargImmune
- Co-I
- MSD (MK3475-427, 005), Anicca, ARCADIAN, Ipsen (CaboPoint 18/2/21), CALYPSO, CAPER, CARES, CellCentric (9/12/20), Eisai (CLEAR 20/6/17), LY314, MITRE, NAXIVA, PRISM, RAMPART, A-PREDICT, STAR, TARGET, IMAGINE
- CROs
- TMC Pharma, Chiltern, Clinipace, Precision for Medicine, ICON, PharmOlam

Non-commercial organizations with actual/potential/perceived conflict of interest of a financial/functional/any other nature

- University of Edinburgh – Senior Clinical Lecturer in Experimental Cancer Medicine
 - 24 funded hours per week
- NHS – Consultant Medical Oncologist (Edinburgh Cancer Centre)
 - 4 funded hours per week (as South East Scotland Cancer Research Network Lead); additional on-call and unfunded work (including renal cancer, registrar teaching, clinical care of trials patients)
- CRUK – Medical Advisor (Centre for Drug Development)
 - 20 funded hours per week
- Collaborating universities (directly linked by research funding/trial funding)
 - University of Glasgow (inc Glasgow CRUK CTU), University of Southampton, University of Leicester, Queens University Belfast, Institute of Cancer Research London

22 February 2024



Cancer Drug Development Forum (CDDF)

Cancer Drug Development Forum asbl

Clos Chapelle-aux-Champs 30, 1200 Woluwe Saint Lambert, Belgium

The CDDF is a non-profit association in the register of legal entities at the French Speaking Enterprise Court in Brussels.

Enterprise number: 738.523.752

 info@cddf.org

 www.cddf.org

 [@cddf_eu](https://twitter.com/cddf_eu)

 [The Cancer Drug Development Forum \(CDDF\)](https://www.linkedin.com/company/the-cancer-drug-development-forum-cddf/)